Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inmune Bio (INMB) EBIT Margin (2021 - 2025)

Inmune Bio's EBIT Margin history spans 5 years, with the latest figure at 19810.0% for Q1 2025.

  • For Q1 2025, EBIT Margin rose 5888286.0% year-over-year to 19810.0%; the TTM value through Sep 2025 reached 102752.0%, down 383057.0%, while the annual FY2024 figure was 304535.71%, 28534797.0% down from the prior year.
  • EBIT Margin for Q1 2025 was 19810.0% at Inmune Bio, up from 78692.86% in the prior quarter.
  • Across five years, EBIT Margin topped out at 3974.23% in Q1 2022 and bottomed at 113700.0% in Q1 2021.
  • The 5-year median for EBIT Margin is 19810.0% (2025), against an average of 32314.32%.
  • The largest annual shift saw EBIT Margin soared 10972577bps in 2022 before it plummeted -6179023bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 5539.88% in 2021, then dropped by -5bps to 5816.49% in 2022, then crashed by -414bps to 29925.0% in 2023, then tumbled by -163bps to 78692.86% in 2024, then soared by 75bps to 19810.0% in 2025.
  • Per Business Quant, the three most recent readings for INMB's EBIT Margin are 19810.0% (Q1 2025), 78692.86% (Q1 2024), and 29925.0% (Q4 2023).